In immuno-oncology (IO) research, biomarkers present the opportunity to identify and target the patient response to a potential new therapeutic, but how can it be integrated into a clinical development plan to increase the effectiveness of clinical trials?
With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, sponsors will increase the success of biomarker integration in their clinical trials.
Amanda Finan Ph.D., Head of R&D IHC, Cerba Research
Amanda Finan received her PhD in Cell Biology from Case Western Reserve University (Cleveland, OH, USA) studying cardiac gene therapy and stem cell biology at the Cleveland Clinic. She then transferred to France with a Marie Curie post-doctoral fellow to continue her research in cardiac regeneration in an INSERM laboratory in Montpellier. Amanda joined the R&D team focused on IHC at Cerba Research in 2018 and at the beginning of 2020 was promoted to Manager of IHC R&D. Amanda has extensive experience in physiology with a particular focus on immunohistochemistry and imaging.
Eitan Akirav Ph.D., VP, BD, Global Lead - Biomarkers, Cerba Research
Dr. Eitan Akirav is VP of Business Development, Global Lead of Biomarkers at Cerba Research, where the biomarker team is focused on providing a comprehensive solution for preclinical and clinical research. Dr. Akirav completed his Ph.D. and postdoctoral training from Yale University and his M.Sc. from the University of Toronto. He is also an Assistant Professor at Stony Brook University, New York. His past research focused on cell-free circulating DNA for the detection of autoimmune diseases. He has authored more than 25 peer-reviewed papers and book chapters.
Who Should Attend?
- Research & Development Managers & Scientists
- Clinical Operations
- Program Development and Management
- Translational Researchers
- Clinical Outsourcing
What You Will Learn
- Overview of biomarkers in IO drug development
- Why biomarker validation and selection is critical for clinical development
- Comprehensive approach of biomarker design
- Identification of biomarkers
- Understand biomarker mechanisms with IHC
Headquartered in Belgium, Cerba Research is a global central and specialist laboratory. Our footprint includes 6 harmonized central lab locations in Ghent, New York, Johannesburg, Shanghai, Taipei and Sydney, as well as Cerba’s large network of labs, pathologists and supporting logistics in Africa. Our network of specialty labs support our core therapy expertise in three distinct areas – Oncology, Liver Indications & Infectious Disease.
From the translation of preclinical to clinical, and on to commercialization, we support emerging and established biotechs and large global pharma clients through close partnering, scientific collaboration and high contact frequency to optimize therapeutic development and obtain critical insights.